Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 15 Jun 2018 Planned number of patients changed from 80 to 110.
- 02 Jun 2018 Status changed from active, no longer recruiting to recruiting.
- 12 Apr 2018 Status changed from recruiting to active, no longer recruiting.